Effects of 1,4-phenylenebis(methylene)selenocyanate on mutagenesis and p53 protein expression in the tongue of lacI rats treated with 4-nitroquinoline-N-oxide

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 634, Issue 1-2, 2007, Pages 146-155

  Guttenplan, Joseph ^a,b   Chen, Kun Ming ^c   Khmelnitsky, Michael ^a   Kosinska, Wieslawa ^a   Hennessy, Jeannie ^c   Bruggeman, Richard ^c   Desai, Dhimant ^c   Amin, Shantu ^c   Sun, Yuan Wan ^c   Spratt, Tomas E ^c   El Bayoumy, Karam ^c  

^a Jaffe Food Allergy Institute   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

4 NQO; Chemoprevention; Cll; Mutagenesis; Oral; p XSC; Selenium

Indexed keywords

1,4 PHENYLENEBIS(METHYLENE)SELENOCYANATE; 4 NITROQUINOLINE 1 OXIDE; ORGANOSELENIUM DERIVATIVE; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DNA DAMAGE; GROWTH INHIBITION; MALE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TONGUE; WESTERN BLOTTING;

4-NITROQUINOLINE-1-OXIDE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTICARCINOGENIC AGENTS; CARCINOGENS; MUTAGENS; ORGANOSELENIUM COMPOUNDS; QUINOLONES; RATS; RATS, INBRED F344; TONGUE; TONGUE NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; RATTUS;

EID: 35448957966     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2007.07.005     Document Type: Article

References (47)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., and Thun M.J. Cancer statistics 2006. CA Cancer J. Clin. 56 (2006) 106-130
2. K.P. Stewart BW (Eds.), World Cancer Report, 2003.
3. Parkin D.M., Laara E., and Muir C.S. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int. J. Cancer 41 (1988) 184-197
4. Parkin D.M., Pisani P., and Ferlay J. Global cancer statistics. CA Cancer J. Clin. 49 (1999) 33-64 31
5. Parkin D.M., Pisani P., and Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer 80 (1999) 827-841
6. Mackenzie J., Ah-See K., Thakker N., Sloan P., Maran A.G., Birch J., and Macfarlane G.J. Increasing incidence of oral cancer amongst young persons: what is the aetiology?. Oral Oncol. 36 (2000) 387-389
7. Magrath I., and Litvak J. Cancer in developing countries: opportunity and challenge. J. Natl. Cancer Inst. 85 (1993) 862-874
8. Davis S., and Severson R.K. Increasing incidence of cancer of the tongue in the United States among young adults. Lancet 2 (1987) 910-911
9. Suzui M., Yoshimi N., Tanaka T., and Mori H. Infrequent Ha-ras mutations and absence of Ki-ras, N-ras, and p53 mutations in 4-nitroquinoline 1-oxide-induced rat oral lesions. Mol. Carcinogen 14 (1995) 294-298
10. Kramer I.R., Lucas R.B., Pindborg J.J., and Sobin L.H. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg. Oral Med. Oral Pathol. 46 (1978) 518-539
11. Tanaka T., Kojima T., Okumura A., Yoshimi N., and Mori H. Alterations of the nucleolar organizer regions during 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in rats. Carcinogenesis 12 (1991) 329-333
12. Jovanovic A., van der Tol I.G., Schulten E.A., Kostense P.J., de Vries N., Snow G.B., and van der I. Waal Risk of multiple primary tumors following oral squamous-cell carcinoma. Int. J. Cancer 56 (1994) 320-323
13. Licciardello J.T., Spitz M.R., and Hong W.K. Multiple primary cancer in patients with cancer of the head and neck: second cancer of the head and neck, esophagus, and lung. Int. J. Radiat. Oncol. Biol. Phys. 17 (1989) 467-476
14. Franco E.L., Kowalski L.P., and Kanda J.L. Risk factors for second cancers of the upper respiratory and digestive systems: a case-control study. J. Clin. Epidemiol. 44 (1991) 615-625
15. Lippman S.M., Sudbo J., and Hong W.K. Oral cancer prevention and the evolution of molecular-targeted drug development. J. Clin. Oncol. 23 (2005) 346-356
16. Canto M.T., and Devesa S.S. Oral cavity and pharynx cancer incidence rates in the United States, 1975-1998. Oral Oncol. 38 (2002) 610-617
17. El-Bayoumy K., and Sinha R. Molecular chemoprevention by selenium: a genomic approach. Mutat. Res. 591 (2005) 224-236
18. Schwartz J.L., Gu X., Kittles R.A., Baptiste A., and Shklar G. Experimental oral carcinoma of the tongue and buccal mucosa: possible biologic markers linked to cancers at two anatomic sites. Oral Oncol. 36 (2000) 225-235
19. Tanaka T., Makita H., Kawabata K., Mori H., and El-Bayoumy K. 1,4-Phenylenebis(methylene)selenocyanate exerts exceptional chemopreventive activity in rat tongue carcinogenesis. Cancer Res. 57 (1997) 3644-3648
20. Sinha R., and El-Bayoumy K. Apoptosis is a critical cellular event in cancer chemoprevention and chemotherapy by selenium compounds. Curr. Cancer Drug Targets 4 (2004) 13-28
21. Ghose A., Fleming J., El-Bayoumy K., and Harrison P.R. Enhanced sensitivity of human oral carcinomas to induction of apoptosis by selenium compounds: involvement of mitogen-activated protein kinase and Fas pathways. Cancer Res. 61 (2001) 7479-7487
22. Richie Jr. J.P., Kleinman W., Desai D.H., Das A., Amin S.G., Pinto J.T., and El-Bayoumy K. The organoselenium compound 1,4-phenylenebis(methylene)selenocyanate inhibits 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced tumorgenesis and enhances glutathione-related antioxidant levels in A/J mouse lung. Chem. Biol. Interact. 161 (2006) 93-103
23. Rosa J.G., Prokopczyk B., Desai D.H., Amin S.G., and El-Bayoumy K. Elevated 8-deoxyguanosine levels in lung DNA of A/J mice and F344 rat treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and inhibition by dietary 1,4-phenylenebis(methylene)selenocyanate. Carcinogenesis 19 (1998) 1783-1788
24. Hakura A., Tsutsui Y., Sonoda J., Kai J., Imade T., Shimada M., Sugihara Y., and Mikami T. Comparison between in vivo mutagenicity and carcinogenicity in multiple organs by benzo[a]pyrene in the lacZ transgenic mouse (Muta Mouse). Mutat. Res. 398 (1998) 123-130
25. Lambert I.B., Singer T.M., Boucher S.E., and Douglas G.R. Detailed review of transgenic rodent mutation assays. Mutat. Res. 590 (2005) 1-280
26. van Delft J.H., Bergmans A., van Dam F.J., Tates A.D., Howard L., Winton D.J., and Baan R.A. Gene-mutation assays in lambda lacZ transgenic mice: comparison of lacZ with endogenous genes in splenocytes and small intestinal epithelium. Mutat. Res. 415 (1998) 85-96
27. Jones C.J., Edwards S.M., and Waters R. The repair of identified large DNA adducts induced by 4-nitroquinoline-1-oxide in normal or xeroderma pigmentosum group A human fibroblasts, and the role of DNA polymerases alpha or delta. Carcinogenesis 10 (1989) 1197-1201
28. Greenblatt M.S., Bennett W.P., Hollstein M., and Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54 (1994) 4855-4878
29. Hollstein M.C., Sidransky D., Vogelstein B., and Harris C.C. p53 mutations in human cancer. Science 253 (1991) 49-53
30. Hussain S.P., and Harris C.C. Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res. 58 (1998) 4023-4037
31. Boyle J.O., Hakim J., Koch W., van der Riet P., Hruban R.H., Roa R.A., Correo R., Eby Y.J., Ruppert J.M., and Sidransky D. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 53 (1993) 4477-4480
32. Brennan J.A., Boyle J.O., Koch W.M., Goodman S.N., Hruban R.H., Eby Y.J., Couch M.J., Forastiere A.A., and Sidransky D. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 332 (1995) 712-717
33. Soni S., Kaur J., Kumar A., Chakravarti N., Mathur M., Bahadur S., Shukla N.K., Deo S.V., and Ralhan R. Alterations of rb pathway components are frequent events in patients with oral epithelial dysplasia and predict clinical outcome in patients with squamous cell carcinoma. Oncology 68 (2005) 314-325
34. Raju B., Mehrotra R., Oijordsbakken G., Al-Sharabi A.K., Vasstrand E.N., and Ibrahim S.O. Expression of p53, cyclin D1 and Ki-67 in pre-malignant and malignant oral lesions: association with clinicopathological parameters. Anticancer Res. 25 (2005) 4699-4706
35. Hussain S.P., and Harris C.C. p53 biological network: at the crossroads of the cellular-stress response pathway and molecular carcinogenesis. J. Nippon Med. School-Nihon Ika Daigahu Zasshi 73 (2006) 54-64
36. Zimmer D.M., Harbach P.R., Mattes W.B., and Aaron C.S. Comparison of mutant frequencies at the transgenic lambda Lacl and cll/cl loci in control and ENU-treated Big Blue Mice. Environ. Mol. Mutag. 33 (1999) 249-256
37. Jakubczak J.L., Merlino G., French J.E., Muller W.J., Paul B., Adhya S., and Garges S. Analysis of genetic instability during mammary tumor progression using a novel selection-based assay for in vivo mutations in a bacteriophage transgene target. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 9073-9078
38. Guttenplan J.B., Kosinska W., von Pressentin M.M., Rosa J., and El-Bayoumy K. Effects of 1,4-phenylenebis(methylene)selenocyanate (p-XSC) and vitamin E on 4-nitroquinoline-N-oxide (4-NQO)-induced mutagenesis in lacZ mouse upper aerodigestive tissue. Mutat. Res. 518 (2002) 85-93
39. von Pressentin M.M., Kosinska W., and Guttenplan J.B. Mutagenesis induced by oral carcinogens in lacZ mouse (Muta Mouse) tongue and other oral tissues. Carcinogenesis 20 (1999) 2167-2170
40. Suzuki T. Target organ and time-course in the mutagenicity of five carcinogens in Muta Mouse: a summary report of the second collaborative study of the transgenic mouse mutation assay by JEMS/MMS. Mutat. Res. 444 (1999) 259-268
41. Osugi Y. p53 expression in various stages of 4-nitroquinoline 1-oxide induced carcinoma in the rat tongue. J. Osaka Dent. Univ. 30 (1996) 29-35
42. Li T. Expression of p53 protein during 4NQO-induced lingual carcinogenesis in two strains of rats. Zhonghua Kou Qiang Yi Xue Za Zhi 35 (2000) 126-128
43. Fields W.R., Li Y., and Townsend A.J. Protection by transfected glutathione S-transferase isozymes against carcinogen-induced alkylation of cellular macromolecules in human MCF-7 cells. Carcinogenesis 15 (1994) 1155-1160
44. Varnes M.E., and Biaglow J.E. Interactions of the carcinogen 4-nitroquinoline 1-oxide with the non-protein thiols of mammalian cells. Cancer Res. 39 (1979) 2960-2965
45. Lloyd D.R., and Hanawalt P.C. p53 controls global nucleotide excision repair of low levels of structurally diverse benzo(g)chrysene-DNA adducts in human fibroblasts. Cancer Res. 62 (2002) 5288-5294
46. El-Bayoumy K., Chae Y.-H., Upadhyaya P., Meschter C., Cohen L.A., and Reddy B.S. Inhibition of 7,12-dimethylbenz(a)anthracene-induced tumors and DNA adduct formation in the mammary glands of female Sprague-Dawley rats by the synthetic organoselenium compound 1,4-phenylenebis(methylene) selenocyanate. Cancer Res. 52 (1992) 2402-2407
47. el-Bayoumy K. Environmental carcinogens that may be involved in human breast cancer etiology. Chem. Res. Tox. 5 (1992) 585-590